

Ticker: **JNJ.US EQUITY****Johnson & Johnson (New York: JNJ, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website www.jnj.com
Number of Employees 139,800
Ticker: JNJ US

1 Johnson & Johnson Plaza New Brunswick, NJ 08933 United States
Phone : 1-732-524-0400
Fax : --

↑ **156.01** +0.45 (0.29%)


Johnson & Johnson fabrica productos de sanidad y provee servicios relacionados para los mercados de consumo, farmacéuticos, dispositivos médicos y de diagnósticos. Vende productos de piel y cabello, acetaminofénicos, farmacéuticos, equipo de diagnóstico y de cirugía alrededor del mundo.

Stock Quote & Chart (Currency: USD)

Last (delayed quote)	156.01	Market Cap (MM)	375,371.5
Open	155.43	Shares Out. (MM)	2,406.1
Previous Close	155.56	Float %	99.8%
Change	-0.36	Shares sold short (MM)	16,330,615.0
Change %	-0.23	Dividend Yield %	3.2
Day High/Day Low	156.3 / 154.9	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	170.0 / 140.7	P / Diluted EPS Before XO	
Volume (MM)	3.48	Beta	0.47
Avg. Vol - 3 mo (MM)	8.94		

Financial Information (Currency: USD, in mm)

Revenue - LTM	89,331.0	Cash & ST Invest.	24,522
EBIT - LTM	21,164.0	Total Assets	180,104.0
EBITDA - LTM	28,460.0	Total Debt	37,834.0
Net Income - LTM	21,810.0	Total Liabilities	108,614.0
Total Enterprise Value	388,842	Total Equity	71,490.0
TEV/ Total Revenue	4.6 x	Cash from Operations - LTM	24,783.0
TEV/ EBITDA	14.3 x	Cash From Investing - LTM	-18,432.0
		Cash from Financing -LTM	6,650.0

**Company Notes**


2016 Q1	GAAP Net Income Includes: (in millions, pre-tax)
GAAP Net Income Include:(in millions, pre tax)	A gain of \$402.000 from Litigation / Settlement
A loss of \$137 from Restructuring	A loss of \$139.000 from Other One-Time Charges
A loss of \$66 from Litigation	A loss of \$32.000 from Merger expense
	A gain of \$26.000 from Sale of Business
2015 A1	2014 A1
GAAP Net Income includes. (in millions. pre-tax):	GAAP Net Income Includes: (in millions, pre-tax)
a total loss of \$1,237.000	A gain of \$1.899.00 from sale of business
	A loss of \$1,253.000 from Legal Expense
2015 Q4	A loss of \$754.000 from Merger/Acquisition Expense
GAAP Net Income includes, (in millions, pre-tax):	A loss of \$346.000 from Other One Time Items
a loss of \$214.000 from Acquired In-Process R&D Expense	A loss of \$178.000 from acquired in R&D
a gain of \$33.000 from Sale of Business	
a loss of \$590.000 from Restructuring Charges	2014 Q4
a loss of \$83.000 from Other One-Time Charges	GAAP Net Income Includes: (in millions, pre-tax)
	A loss of \$692.000 from Legal/Litigation
2015 Q3	A loss of \$325.000 from Merger/Acquisition Expense
GAAP Net Income Includes: (in millions, pre-tax)	A loss of \$156.000 from Acquired In-Process RD
A loss of \$409.000 from Legal Expense	A loss of \$49.000 from Sale of Business
A loss of \$32.000 from Merger/Acquisition Expense	
A loss of \$10.000 from Acquired In-Process RD	2014 Q3
	GAAP Net Income Includes: (in millions, pre-tax)
2015 Q2	A gain of \$1948.000 from Sale of Business
GAAP Net Income Includes: (in millions, pre-tax)	A loss of \$346.000 from Other One Time Items
A loss of \$134.000 from Legal Expense	A loss of \$285.000 from Legal Expense
A loss of \$49.000 from Merger/Acquisition Expense	A loss of \$167.000 from Merger/Acquisition Expense
A loss of \$9.000 from Other One Time Items	
A gain of \$3.000 from Sale of Business	
2015 Q1	2014 Q2

Key Board Members

Name	Title	Organization
Mark A Weinberger	Co-Founder	Washington Counsel Pc
	Senior Advisor	Stone Canyon Industries Holdin
	Board Member	Jpmorgan Chase & Co
	Board Member	Accelerate Acquisition Corp
	Board Member	Saudi Arabian Oil Co
	Board Member	Johnson & Johnson
	Board Member	Metlife Inc
	Board Member	Just Capital Foundation Inc
	Board Member	Concord Coalition
	Board Member	National Bureau Of Economic Re
	Trustee	Case Western Reserve Universit
	Trustee	Emory University
	Board Member	Bullis School
	Trustee	United States Council For Inte
Hubert Joly	Senior Lecturer:Business Administ	Harvard Business School
	Board Member	Johnson & Johnson
	Board Member	Minnesota Business Partnership
	Lead Director	Ralph Lauren Corp
Daniel Eduardo Pinto	Vice Chairman	Jpmorgan Chase & Co
	Board Member	Johnson & Johnson
	Board Member	Institute Of International Fin
Mark B Mcclellan	Founding Dir:Margolis Center For I	Duke University
	Senior Advisor	Blackstone Inc
	Board Member	Cigna Group/The
	Board Member	Gary & Mary West Wireless Heal
	Board Member	Alignment Healthcare Inc
	Board Member	Johnson & Johnson
	Board Member	Long Term Quality Alliance
	Board Member	Prognomiq Inc


Ticker: JNJ US EQUITY		Johnson & Johnson										
Period Type		Annuals		Sector: Salud			Industry: Productos farmacéuticos			Sub-Industry: Productos farmacéuticos		
Annuals												
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY	
Key Financials												
	Actuals							LTM	Estimates			
For the Fiscal Period Ending	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	30/03/2025	30/03/2025	31/12/2025	31/12/2026	31/12/2027	
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
General Motors Company diseña, fabrica y vende autos, camiones, crossovers y partes. Ofrece protección de vehículos, partes, accesorios, mantenimiento, rad												
Total Revenue	81,581.0	82,059.0	82,584.0	93,775.0	79,990.0	85,159.0	88,821.0	21,893.0	88,821.0	22,847.2	22,847.2	
Growth Over Prior Year	6.7%	0.6%	0.6%	13.6%	(14.7%)	6.5%	4.3%	4.3%	1.8%	1.8%	1.8%	
Gross Profit	54,490.0	54,503.0	54,157.0	63,920.0	55,394.0	58,606.0	61,350.0	61,014.0	--	--	--	
Margin %	66.8%	66.4%	65.6%	68.2%	69.3%	68.8%	69.1%	278.7%	--	--	--	
EBITDA	26,978.0	27,389.0	27,264.0	31,337.0	27,400.0	29,382.0	28,577.0	28,460.0	8,601.5	8,601.5	8,601.5	
Margin %	33.1%	33.4%	33.0%	33.4%	34.3%	34.5%	32.2%	130.0%	9.7%	37.6%	37.6%	
EBIT	20,049.0	20,080.0	19,733.0	23,647.0	20,230.0	21,696.0	21,038.0	21,164.0	7,628.5	7,628.5	7,628.5	
Margin %	24.6%	24.5%	23.9%	25.2%	25.3%	25.5%	23.7%	96.7%	8.6%	33.4%	33.4%	
Earnings from Cont. Ops.	15,297.0	15,119.0	14,714.0	20,878.0	16,370.0	13,326.0	14,066.0	21,810.0	--	--	--	
Margin %	18.8%	18.4%	17.8%	22.3%	20.5%	15.6%	15.8%	99.6%	--	--	--	
Net Income	15,297.0	15,119.0	14,714.0	20,878.0	17,941.0	35,153.0	14,066.0	21,810.0	6,464.3	6,464.3	6,464.3	
Margin %	18.8%	18.4%	17.8%	22.3%	22.4%	41.3%	15.8%	99.6%	7.3%	28.3%	28.3%	
Diluted EPS Excl. Extra Items	5.6	5.6	5.5	7.8	6.1	5.2	5.8	9.0	2.7	2.7	2.7	
Growth Over Prior Year	1,093.6%	0.4%	(2.1%)	41.7%	(21.4%)	(15.3%)	11.3%	32.6%	(4.6%)	(4.6%)	(4.6%)	

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	156.01
Shares Out.	2,406.07
Market Capitalization (USD)	375,371.49
- Cash & Short Term Investments	38,781.00
+ Total Debt	52,252.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	388,842.49
Book Value of Common Equity	78,109.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	52,252.00
= Total Capital	130,361.00



Valuation Multiples based on Current Capitalization				
For the Fiscal Period Ending	Actual	LTM	Estimates	
	30/03/2025	30/03/2025	30/03/2025	30/03/2025
TEV/Total Revenue	4.1x	4.6x	16.9x	16.9x
TEV/EBITDA	12.7x	14.3x	11.4x	11.4x
TEV/EBIT	17.2x	19.2x	12.8x	12.8x
P/Diluted EPS Before Extra	25.1x	18.2x		
P/BV	4.9x	5.0x	5.0x	5.0x
Price/Tang BV	--	--		

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	18.5x	14.8x	14.8x	14.8x
TEV / EBITDA	14.3x	11.4x	11.4x	11.4x
Price / CF	15.2x	14.1x	14.1x	14.1x
Price / Book	4.8x	5.0x	5.0x	5.0x
Dividend Yield	3.2x	3.2x	3.2x	3.2x



Ticker:	JNJ US EQUITY	JNJ US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Income Statement											
Income Sheet as of:	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	29/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00	79,990.00	85,159.00	88,821.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
Total Revenue	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00	79,990.00	85,159.00	88,821.00
Cost Of Goods Sold	22,746.00	21,536.00	21,685.00	25,439.00	27,091.00	27,556.00	28,427.00	29,855.00	24,596.00	26,553.00	27,471.00
Gross Profit	51,585.00	48,538.00	50,205.00	51,011.00	54,490.00	54,503.00	54,157.00	63,920.00	55,394.00	58,606.00	61,350.00
Selling General & Admin Exp.	22,132.00	21,427.00	19,974.00	21,928.00	23,666.00	23,068.00	22,265.00	25,559.00	21,029.00	21,825.00	23,080.00
R & D Exp.	8,494.00	9,046.00	9,095.00	10,594.00	10,775.00	11,355.00	12,159.00	14,714.00	14,135.00	15,085.00	17,232.00
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
Operating Expense, Total	30,626.00	30,473.00	29,069.00	32,522.00	34,441.00	34,423.00	34,424.00	40,273.00	35,164.00	36,910.00	40,312.00
Operating Income	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00	20,230.00	21,696.00	21,038.00
Interest Expense	533.00	552.00	726.00	934.00	1,005.00	318.00	201.00	183.00	276.00	772.00	755.00
Interest Income	67.00	128.00	368.00	385.00	611.00	357.00	111.00	53.00	490.00	1,261.00	1,332.00
Net Interest Exp.	466.00	424.00	358.00	549.00	394.00	(39.00)	90.00	130.00	(214.00)	(489.00)	(577.00)
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,088.00	910.00	863.00	619.00	2,873.00	4,945.00	3,257.00	1,358.00	1,465.00	7,240.00	770.00
EBT Excl. Unusual Items	19,405.00	16,731.00	19,915.00	17,321.00	16,782.00	15,174.00	16,386.00	22,159.00	18,979.00	14,945.00	20,845.00
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	(2,383.00)	(2,583.00)	(563.00)	(1,307.00)	(1,217.00)	(2,154.00)	(111.00)	(617.00)	(380.00)	(117.00)	(226.00)
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	1,225.00	118.00	675.00	955.00	-	-	-	-	-	-	4,384.00
Other Unusual Items	2,316.00	4,930.00	(224.00)	704.00	2,434.00	4,308.00	222.00	1,234.00	760.00	234.00	(8,316.00)
EBT Incl. Unusual Items	20,563.00	19,196.00	19,803.00	17,673.00	17,999.00	17,328.00	16,497.00	22,776.00	19,359.00	15,062.00	16,687.00
Income Tax Expense	4,240.00	3,787.00	3,263.00	16,373.00	2,702.00	2,209.00	1,783.00	1,898.00	2,989.00	1,736.00	2,621.00
Earnings from Cont. Ops.	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00	16,370.00	13,326.00	14,066.00
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	(1,571.00)	(21,827.00)	-
Minority Int. in Earnings	-	-	-	-	-	-	-	-	-	-	-
Net Income	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00	17,941.00	35,153.00	14,066.00
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00	17,941.00	35,153.00	14,066.00
Abnormal Losses (Gains)	(1,751.00)	(671.00)	1,685.00	3,752.00	4,270.00	6,413.00	4,713.00	2,991.00	4,670.00	10,217.00	7,766.00
Tax Effect on Abnormal Items	984.05	241.85	(342.90)	12,507.00	(1,286.70)	(1,885.07)	(1,257.03)	(1,599.50)	(683.23)	(1,856.33)	(1,472.00)
NI to Common Excl. Extra Items	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,169.97	22,269.50	21,927.77	43,513.67	20,360.00
Per Share Items											
Basic EPS	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93	6.83	13.88	5.84
Basic EPS Excl. Extra Items	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93	6.23	5.26	5.84
Weighted Avg. Basic Shares Out.	2,815.20	2,771.80	2,737.30	2,692.00	2,681.50	2,645.10	2,632.80	2,632.10	2,625.20	2,533.50	2,407.30
Diluted EPS	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81	6.73	13.72	5.79
Diluted EPS Excl. Extra Items	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81	6.14	5.20	5.79
Weighted Avg. Diluted Shares Out.	2,863.90	2,812.90	2,788.90	2,745.30	2,728.70	2,684.30	2,670.70	2,674.00	2,663.90	2,560.40	2,429.40
Normalized Basic EPS	5.97	6.20	6.73	7.30	8.18	8.68	8.03	9.80	10.15	9.92	9.98
Normalized Diluted EPS	5.43	5.33	6.41	6.39	6.70	7.32	6.80	8.33	7.64	8.47	8.38
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	47.60	53.07	52.13	687.50	62.05	65.61	71.21	52.82	71.36	89.36	84.03
Supplemental Items											
EBITA	22,354.00	19,311.00	22,390.00	21,531.00	24,378.00	24,889.00	24,664.00	28,637.00	25,000.00	26,782.00	25,764.00
EBIT	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00	20,230.00	21,696.00	21,038.00
As Reported Total Revenue*	-	-	-	-	81,581.00	82,059.00	82,584.00	93,775.00	79,990.00	85,159.00	88,821.00
Effective Tax Rate %	20.62	19.73	16.48	92.64	15.01	12.75	10.81	8.33	15.44	11.53	15.71
Normalized Net Income	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,169.97	22,269.50	20,356.77	21,686.67	20,360.00
Interest Capitalized	115.00	102.00	102.00	94.00	86.00	70.00	63.00	49.00	49.00	70.00	79.00
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00	1,138.00	1,162.00	1,176.00
Stock-Based Comp., Total	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00	1,138.00	1,162.00	1,176.00

Ticker:	JNJ US EQUITY	JNJ US EQUITY	Ascend ▾	Currency	Reporting	Change	USD
Period Type	Annuals ▾	Consolidated	Yes ▾	Accounting	Mixed ▾		

Johnson & Johnson

	Sector: Salud			Industry: Productos farmacéuticos			Sub-Industry: Productos farmacéuticos				
Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	29/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	14,523.00	13,732.00	18,972.00	17,824.00	18,107.00	17,305.00	13,985.00	14,487.00	12,889.00	21,859.00	24,105.00
Short Term Investments	18,566.00	24,644.00	22,935.00	472.00	1,580.00	1,982.00	11,200.00	17,121.00	9,392.00	1,068.00	417.00
Total Cash & ST Investments	33,089.00	38,376.00	41,907.00	18,296.00	19,687.00	19,287.00	25,185.00	31,608.00	22,281.00	22,927.00	24,522.00
Accounts & Notes Receivable	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	15,283.00	14,039.00	14,873.00	14,842.00
Total Receivables	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	15,283.00	14,039.00	14,873.00	14,842.00
Inventories	8,184.00	8,053.00	8,144.00	8,765.00	8,599.00	9,020.00	9,344.00	10,387.00	10,268.00	11,181.00	12,444.00
Prepaid Exp.	3,486.00	3,047.00	3,282.00	2,537.00	2,699.00	2,392.00	3,132.00	3,701.00	2,876.00	4,514.00	4,085.00
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	-	-	-	-	950.00	94.00	-	-	5,830.00	-	-
Total Current Assets	55,744.00	60,210.00	65,032.00	43,088.00	46,033.00	45,274.00	51,237.00	60,979.00	55,294.00	53,495.00	55,893.00
Net Property, Plant & Equipment	16,126.00	15,905.00	15,912.00	17,005.00	17,035.00	18,615.00	18,766.00	18,962.00	17,982.00	19,898.00	20,518.00
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	6,202.00	5,490.00	6,148.00	7,105.00	7,640.00	7,819.00	8,534.00	10,223.00	8,947.00	9,279.00	10,461.00
Other Long-Term Assets	52,286.00	51,806.00	54,116.00	90,105.00	82,246.00	86,020.00	96,357.00	91,854.00	105,155.00	84,886.00	93,232.00
Total Assets	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	182,018.00	187,378.00	167,558.00	180,104.00
LIABILITIES											
Accrued Exp.	13,314.00	7,914.00	13,714.00	10,163.00	12,478.00	14,237.00	14,997.00	17,198.00	13,768.00	14,205.00	12,675.00
Short-term Borrowings	3,638.00	7,004.00	4,684.00	3,906.00	2,796.00	1,471.00	2,631.00	3,766.00	12,756.00	3,451.00	5,983.00
Accounts Payable	7,633.00	6,668.00	6,918.00	7,310.00	7,537.00	8,544.00	9,505.00	11,055.00	9,889.00	9,632.00	10,311.00
Curr. Income Taxes Payable	446.00	750.00	971.00	1,854.00	818.00	2,266.00	1,392.00	1,112.00	2,220.00	2,993.00	3,772.00
Other Current Liabilities	-	5,411.00	-	7,304.00	7,601.00	9,446.00	13,968.00	12,095.00	17,169.00	16,001.00	17,580.00
Total Current Liabilities	25,031.00	27,747.00	26,287.00	30,537.00	31,230.00	35,964.00	42,493.00	45,226.00	55,802.00	46,282.00	50,321.00
Long-Term Debt	15,122.00	12,857.00	22,442.00	30,675.00	27,684.00	27,210.00	33,735.00	30,985.00	27,986.00	26,981.00	31,851.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	20,453.00	21,657.00	22,061.00	35,931.00	34,288.00	35,083.00	35,388.00	31,784.00	26,786.00	25,521.00	26,442.00
Total Liabilities	60,606.00	62,261.00	70,790.00	97,143.00	93,202.00	98,257.00	111,616.00	107,995.00	110,574.00	98,784.00	108,614.00
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Additional Paid In Capital	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00
Retained Earnings	97,245.00	103,879.00	110,551.00	101,793.00	106,216.00	110,659.00	113,890.00	123,060.00	128,345.00	153,843.00	155,791.00
Treasury Stock	(19,891.00)	(22,684.00)	(28,352.00)	(31,554.00)	(34,362.00)	(38,417.00)	(38,490.00)	(39,099.00)	(41,694.00)	(75,662.00)	(75,680.00)
Comprehensive Inc. and Other	(10,722.00)	(13,165.00)	(14,901.00)	(13,199.00)	(15,222.00)	(15,891.00)	(15,242.00)	(13,058.00)	(12,967.00)	(12,527.00)	(11,741.00)
Total Common Equity	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	74,023.00	76,804.00	68,774.00	71,490.00
Total Equity	69,752.00	71,150.00	70,418.00	60,160.00	59,752.00	59,471.00	63,278.00	74,023.00	76,804.00	68,774.00	71,490.00
Total Liabilities And Equity	130,358.00	133,411.00	141,208.00	157,303.00	152,954.00	157,728.00	174,894.00	182,018.00	187,378.00	167,558.00	180,104.00
Supplemental Items											
Total Shares Out. on Filing Date	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97	2,613.60	2,407.08	2,406.92
Total Shares Out. on Balance Sheet Date	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97	2,613.60	2,407.08	2,406.92
Book Value/Share	25.06	25.82	26.02	22.43	22.44	22.59	24.04	28.16	29.39	28.57	29.70
Tangible Book Value	20,698.00	23,757.00	20,737.00	(24,974.00)	(18,312.00)	(21,811.00)	(26,517.00)	(7,615.00)	2,268.00	(1,959.00)	(10,328.00)
Tangible Book Value/Share	7.44	8.62	7.66	(9.31)	(6.88)	(8.29)	(10.07)	(2.90)	0.87	(0.81)	(4.29)
Total Debt	18,760.00	19,861.00	27,126.00	34,581.00	30,480.00	28,681.00	36,366.00	34,751.00	40,742.00	30,432.00	37,834.00
Net Debt	(14,329.00)	(18,515.00)	(14,781.00)	16,285.00	10,793.00	9,394.00	11,181.00	3,143.00	18,461.00	7,505.00	13,312.00
Total Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Inventory Method	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out	First-in-first-out
Raw Materials in Inventory	1,214.00	936.00	952.00	1,140.00	1,114.00	1,117.00	1,410.00	1,592.00	1,719.00	2,355.00	2,337.00
Work in Progress Inventory	2,461.00	2,241.00	2,185.00	2,317.00	2,109.00	1,832.00	2,040.00	2,287.00	1,577.00	1,952.00	2,815.00
Finished Goods Inventory	4,509.00	4,876.00	5,007.00	5,308.00	5,376.00	6,071.00	5,894.00	6,508.00	6,972.00	6,874.00	7,292.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	275.00	268.00	252.00	291.00	248.00	226.00	293.00	230.00	169.00	166.00	167.00
Full Time Employees	126,500.00	127,100.00	126,400.00	134,000.00	135,100.00	132,200.00	134,500.00	141,700.00	152,700.00	134,400.00	139,800.00

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Cash Flow											
For the Fiscal Period Ending	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	29/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Net Income	16,323.00	15,409.00	16,540.00	1,300.00	15,297.00	15,119.00	14,714.00	20,878.00	17,941.00	35,153.00	14,066.00
Depreciation & Amort., Total	3,895.00	3,746.00	3,754.00	5,642.00	6,929.00	7,009.00	7,231.00	7,390.00	6,970.00	7,486.00	7,339.00
Other Non-Cash Adj	(1,335.00)	1,009.00	(869.00)	11,441.00	(2,147.00)	(2,206.00)	(4,059.00)	(3,645.00)	(998.00)	(20,247.00)	2,774.00
Changes in Non-Cash Capital	(173.00)	(595.00)	(658.00)	2,673.00	2,122.00	3,494.00	5,650.00	(1,213.00)	(2,719.00)	399.00	87.00
Cash from Ops.	18,710.00	19,569.00	18,767.00	21,056.00	22,201.00	23,416.00	23,536.00	23,410.00	21,194.00	22,791.00	24,266.00
Capital Expenditure	(3,714.00)	(3,463.00)	(3,226.00)	(3,279.00)	(3,670.00)	(3,498.00)	(3,347.00)	(3,652.00)	(4,009.00)	(4,543.00)	(4,424.00)
Sale of Property, Plant, and Equipment	4,631.00	3,464.00	1,267.00	1,832.00	3,203.00	3,265.00	305.00	711.00	543.00	358.00	675.00
Cash Acquisitions	-	-	-	-	-	-	-	-	-	(470.00)	(1,783.00)
Proceeds from Investment	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	-	-	-	-	-
Invest. in Marketable & Equity Secur.	(34,913.00)	(40,828.00)	(33,950.00)	(6,153.00)	(5,626.00)	(3,920.00)	(21,089.00)	(30,394.00)	(32,384.00)	(10,906.00)	(1,726.00)
Other Investing Activities	21,691.00	33,092.00	31,148.00	(7,268.00)	2,926.00	(2,041.00)	3,306.00	24,652.00	23,479.00	16,439.00	(11,341.00)
Cash from Investing	(12,305.00)	(7,735.00)	(4,761.00)	(14,868.00)	(3,167.00)	(6,194.00)	(20,825.00)	(8,683.00)	(12,371.00)	878.00	(18,599.00)
Net Short Term Debt Issued/Repaid	596.00	1,372.00	(1,906.00)	(461.00)	(2,374.00)	(61.00)	728.00	807.00	9,584.00	(9,230.00)	5,814.00
Long-Term Debt Issued	2,098.00	75.00	12,004.00	8,992.00	5.00	3.00	7,431.00	5.00	2.00	-	6,660.00
Long-Term Debt Repaid	(1,844.00)	(68.00)	(2,223.00)	(1,777.00)	(1,555.00)	(2,823.00)	(1,064.00)	(1,802.00)	(2,134.00)	(1,551.00)	(1,453.00)
Total Debt Issued/Repaid	850.00	1,379.00	7,875.00	6,754.00	(3,924.00)	(2,881.00)	7,095.00	(990.00)	7,452.00	(10,781.00)	11,021.00
Pref. Dividends Paid	(7,768.00)	(8,173.00)	(8,621.00)	(8,943.00)	(9,494.00)	(9,917.00)	(10,481.00)	(11,032.00)	(11,682.00)	(11,770.00)	(11,823.00)
Total Dividends Paid	(7,768.00)	(8,173.00)	(8,621.00)	(8,943.00)	(9,494.00)	(9,917.00)	(10,481.00)	(11,032.00)	(11,682.00)	(11,770.00)	(11,823.00)
Increase in Capital Stocks	1,543.00	1,005.00	1,189.00	1,062.00	949.00	954.00	1,114.00	1,036.00	1,329.00	1,094.00	838.00
Decrease in Capital Stocks	(7,124.00)	(5,290.00)	(8,979.00)	(6,358.00)	(5,868.00)	(6,746.00)	(3,221.00)	(3,456.00)	(6,035.00)	(5,054.00)	(2,432.00)
Special Dividend Paid	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) in Deposits	-	-	-	-	-	-	-	-	-	-	-
Incr(Decr) Insurance Reserves	-	-	-	-	-	-	-	-	-	-	-
Other Financing Activities	(310.00)	(1,546.00)	(230.00)	149.00	(414.00)	566.00	(538.00)	217.00	(247.00)	10,574.00	(1,025.00)
Cash from Financing	(12,809.00)	(12,625.00)	(8,766.00)	(7,336.00)	(18,751.00)	(18,024.00)	(6,031.00)	(14,225.00)	(9,183.00)	(15,937.00)	(3,421.00)
Net Change in Cash	(6,404.00)	(791.00)	5,240.00	(1,148.00)	283.00	(802.00)	(3,320.00)	502.00	(360.00)	7,732.00	2,246.00
Supplemental Items											
Cash Interest Paid	603.00	617.00	730.00	960.00	1,049.00	995.00	904.00	990.00	982.00	1,836.00	1,990.00
Cash Taxes Paid	3,536.00	2,865.00	2,843.00	3,312.00	4,570.00	4,191.00	4,619.00	4,768.00	5,223.00	8,574.00	6,714.00
Free Cash Flow	14,996.00	16,106.00	15,541.00	17,777.00	18,531.00	19,918.00	20,189.00	19,758.00	17,185.00	18,248.00	19,842.00
Change in Net Working Capital	-	-	-	-	-	-	-	-	-	-	-

Ticker: JNJ US EQUITY

Period Type: Annuals

Sort: Ascend

Consolidated: Yes

Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples												
		28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	29/12/2024
TEV / LTM Total Revenue	Close	3.7x	3.8x	4.1x	5.1x	4.3x	4.8x	5.2x	4.8x	6.0x	4.5x	4.1x
	Average	3.8x	3.5x	4.2x	4.7x	4.9x	4.5x	4.8x	5.4x	4.9x	5.3x	4.5x
	High	4.1x	3.8x	4.7x	5.2x	5.4x	4.9x	5.2x	5.9x	6.0x	6.1x	4.8x
	Low	3.3x	3.2x	3.5x	4.0x	4.3x	4.2x	3.7x	4.8x	4.5x	4.5x	4.1x
TEV / LTM EBITDA	Close	11.2x	12.1x	11.9x	16.2x	13.0x	14.4x	15.6x	14.5x	17.5x	13.1x	12.7x
	Average	12.1x	10.6x	13.4x	13.5x	15.5x	13.7x	14.4x	16.4x	14.6x	15.5x	13.0x
	High	13.1x	12.2x	15.0x	16.2x	17.2x	14.7x	15.6x	17.7x	17.5x	17.9x	14.0x
	Low	10.4x	9.5x	11.3x	11.6x	13.1x	12.8x	11.0x	14.5x	13.4x	13.1x	12.0x
TEV / LTM EBIT	Close	13.3x	14.6x	14.1x	21.2x	17.4x	19.5x	21.6x	19.2x	23.7x	17.7x	17.2x
	Average	14.8x	12.5x	16.2x	15.9x	20.2x	18.4x	19.6x	22.6x	19.3x	21.0x	17.6x
	High	16.1x	14.7x	18.1x	21.2x	22.4x	19.8x	21.6x	24.5x	23.7x	24.2x	18.9x
	Low	12.7x	11.3x	13.6x	13.7x	17.6x	17.2x	15.0x	19.2x	17.7x	17.7x	16.3x
Price / LTM EPS	Close	19.3x	19.3x	18.0x	21.9x	19.0x	19.9x	23.1x	20.5x	23.1x	18.5x	17.3x
	Average	18.3x	18.4x	21.3x	20.2x	20.8x	20.1x	19.9x	24.3x	20.7x	21.0x	18.4x
	High	19.8x	19.6x	23.5x	22.4x	23.2x	21.8x	23.1x	26.4x	23.1x	23.6x	19.8x
	Low	15.7x	16.7x	18.0x	17.4x	18.7x	18.8x	15.2x	20.5x	19.0x	18.5x	17.0x
Price / Book Value	Close	4.2x	4.0x	4.4x	6.2x	5.7x	6.5x	6.5x	6.1x	6.0x	5.5x	4.9x
	Average	3.8x	4.0x	4.4x	5.0x	5.9x	6.0x	6.5x	6.9x	6.1x	5.5x	5.4x
	High	4.2x	4.2x	4.9x	6.2x	6.6x	6.5x	6.9x	7.5x	6.6x	6.1x	5.9x
	Low	3.3x	3.6x	3.7x	4.3x	5.3x	5.6x	4.9x	6.1x	5.6x	5.0x	4.9x
Price / Tangible Book Value	Close	14.1x	11.9x	15.0x	--	--	--	--	--	203.6x	--	--
	Average	12.2x	13.4x	13.2x	16.9x	--	--	--	--	203.6x	184.7x	--
	High	14.1x	14.3x	15.0x	18.7x	--	--	--	--	203.6x	207.7x	--
	Low	10.5x	11.9x	11.1x	14.6x	--	--	--	--	203.6x	167.8x	--
Price / Cash Flow	Close	15.8x	14.5x	16.8x	17.9x	15.4x	16.5x	17.6x	19.2x	21.9x	17.4x	14.4x
	Average	16.2x	15.0x	16.1x	18.9x	17.0x	16.3x	16.5x	18.5x	19.4x	19.8x	17.3x
	High	17.6x	16.0x	17.8x	20.9x	18.9x	17.7x	17.6x	20.1x	21.9x	22.3x	18.6x
	Low	14.0x	13.7x	13.6x	16.3x	15.3x	15.2x	12.6x	17.1x	17.8x	17.4x	14.4x
TEV / LTM FCF	Close	19.7x	17.7x	20.3x	21.2x	18.4x	19.4x	20.5x	22.8x	27.0x	21.8x	17.6x
	Average	20.5x	18.7x	19.6x	22.8x	20.1x	19.5x	19.4x	21.6x	23.0x	24.5x	21.6x
	High	22.2x	20.0x	21.6x	25.3x	22.4x	21.2x	20.7x	23.4x	27.0x	27.5x	23.2x
	Low	17.6x	17.0x	16.5x	19.7x	18.1x	18.2x	14.8x	20.0x	21.1x	21.8x	17.6x
Dividend Yield	Close	2.6	2.9	2.7	2.4	2.8	2.6	2.5	2.4	2.5	3.0	3.4
	Average	2.6	2.8	2.6	2.4	2.5	2.6	2.6	2.4	2.4	2.8	3.0
	High	3.0	3.0	3.1	2.8	2.8	2.8	3.4	2.6	2.6	3.1	3.4
	Low	2.4	2.6	2.4	2.2	2.2	2.4	2.4	2.2	2.3	2.5	2.8

Ticker:	JNJ US EQUITY
Period Type:	Quarters

JNJ US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Ratio	-10Q	-9Q	-8Q	-7Q	-6Q	-5Q	-4Q	-3Q	-2Q	-1Q	0Q
For the Fiscal Period Ending											
02/10/202201/01/202302/04/202302/07/202301/16/202301/12/202301/03/202403/06/202429/09/202429/12/202430/03/2025											
Profitability											
Return on Assets	10.2%	9.1%	6.5%	7.1%	20.3%	19.8%	20.9%	20.4%	8.5%	8.1%	11.9%
Return on Capital	17.2%	15.1%	10.9%	11.8%	34.0%	33.1%	34.4%	32.9%	14.8%	14.1%	19.2%
Return on Equity	24.9%	22.3%	16.7%	17.2%	47.5%	46.3%	54.6%	51.8%	20.8%	20.1%	29.4%
Margin Analysis											
Gross Margin	69.1%	69.5%	68.0%	70.0%	69.1%	68.2%	69.6%	69.4%	69.0%	68.3%	66.4%
SG&A Margin	24.8%	26.7%	23.4%	25.0%	25.3%	27.1%	24.6%	25.3%	24.4%	28.6%	23.3%
EBITDA Margin	32.5%	34.0%	34.6%	35.2%	35.2%	34.3%	34.3%	34.1%	33.0%	31.9%	31.9%
EBT Margin	24.2%	25.3%	25.9%	26.4%	26.4%	25.5%	25.7%	24.7%	23.7%	23.7%	23.7%
Earnings from Cont. Ops Margin	26.8%	23.2%	27.7%	27.7%	26.7%	19.9%	28.4%	27.9%	22.6%	16.1%	28.3%
Net Income Margin	22.2%	17.7%	22.3%	23.9%	22.2%	18.9%	25.2%	22.0%	12.0%	19.2%	50.2%
Normalized Net Income Margin	25.6%	22.6%	25.8%	26.8%	27.3%	20.0%	16.6%	26.2%	21.7%	17.5%	26.4%
Free Cash Flow Margin	26.7%	18.9%	11.5%	14.2%	30.5%	29.3%	13.3%	20.7%	31.0%	23.8%	15.4%
Asset Turnover											
Total Asset Turnover	0.7x	0.8x	0.4x	0.8x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x
Fixed Asset Turnover	4.4x	4.7x	4.7x	4.7x	4.7x	4.5x	4.5x	4.7x	4.5x	4.4x	4.4x
Accounts Receivable Turnover	5.4x	5.4x	5.1x	5.0x	5.4x	5.6x	5.4x	5.4x	5.7x	6.0x	5.9x
Inventory Turnover	7.4x	7.1x	7.1x	7.1x	7.5x	7.5x	7.7x	7.1x	7.5x	7.5x	7.4x
Quick Term Liquidity											
Current Ratio	1.4x	1.0x	1.1x	1.1x	1.2x	1.2x	1.2x	1.1x	1.0x	1.1x	1.0x
Quick Ratio	1.1x	0.7x	0.7x	0.7x	0.8x	0.8x	0.8x	0.7x	0.7x	0.7x	0.7x
Cash from Ops. To Fin. Liab.	0.7x	0.4x	0.4x	0.5x	0.5x	0.5x	0.5x	0.5x	0.4x	0.5x	0.7x
Acc. Change Sales/Chg.	66.7x	66.7x	71.7x	66.7x	66.7x	66.7x	66.7x	66.7x	66.7x	66.7x	66.7x
Cash from Investments/Chg.	151.7x	151.7x	171.4x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x
Acc. Change Payables/Chg.	17x	151.7x	171.4x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x	151.7x
Acc. Change Financials/Chg.	67.4x	66.7x	114.0x	101.1x	95.0x	98.0x	101.1x	101.1x	111.5x	91.1x	108.6x
Lower Term Solvency											
Total Debt/Equity	47.9%	52.0%	36.7%	58.7%	47.0%	44.7%	49.0%	50.0%	51.0%	52.0%	46.9%
Total Debt/Total Capital	50.0%	54.7%	47.7%	61.4%	51.4%	50.7%	57.4%	57.4%	58.0%	54.6%	49.1%
Total Debt/Equity	57.0%	60.4%	49.9%	65.1%	56.0%	59.7%	65.8%	66.7%	68.6%	66.6%	49.1%
Total Debt/Total Assets	29.9%	33.8%	29.8%	37.9%	29.7%	29.7%	34.2%	34.2%	35.5%	36.1%	29.4%
Total Liabilities/Total Assets	31.4%	39.7%	33.0%	51.4%	30.4%	31.9%	30.9%	30.7%	31.4%	32.4%	30.1%
EBIT / Interest Exp.	101.1x	36.1x	77.5x	77.5x	70.6x	78.1x	90.1x	71.7x	36.1x	26.4x	101.1x
EBITDA / Interest Exp.	110.2x	36.1x	56.7x	56.7x	50.7x	58.7x	69.7x	60.7x	36.1x	26.4x	101.1x
EBITDA / APBT / Interest Exp.	110.5x	77.7x	72.1x	71.0x	74.1x	79.7x	85.6x	76.1x	70.5x	78.7x	75.1x
Total Debt/EBITDA	1.1x	1.4x	1.0x	1.4x	1.0x	1.0x	1.1x	1.1x	1.4x	1.4x	1.0x
Net Debt/EBITDA	0.07x	0.08x	1.01x	0.07x	0.77x	0.76x	0.76x	0.76x	0.76x	0.47x	0.67x
Adjusted Y. Growth	6.0%	6.3%	6.1%	6.2%	6.3%	6.1%	6.0%	6.4%	6.1%	6.3%	6.4%
Growth Over Nine Year											
Total Revenue	(14.9B)	(15.0B)	5.9%	6.5%	6.9%	7.3%	7.3%	4.3%	5.3%	5.9%	7.4%
Gross Profit	(14.9B)	(15.0B)	7.8%	8.4%	8.7%	9.1%	9.1%	5.5%	6.5%	7.1%	8.4%
EBITDA	(17.0B)	(16.1B)	17.7%	11.8%	6.7%	(4.0B)	7.7%	1.0%	(7.0B)	(9.4B)	1.1%
EBT	(18.1B)	1.7%	13.8%	6.7%	6.7%	(7.0B)	6.7%	6.1%	(7.0B)	(17.0B)	6.1%
EBT	(17.0B)	(4.0B)	14.9%	14.9%	6.1%	(8.1B)	4.8%	5.1%	(10.0B)	(14.9B)	7.1%
Earnings from Cont. Ops	(17.0B)	(15.0B)	(11.0B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)
Net Income	31.4%	(75.7B)	(101.1B)	70.7%	48.9%	16.0%	(4.0B)	(4.0B)	(4.0B)	(15.7B)	77.0%
Normalized Net Income	(14.9B)	(15.0B)	5.9%	6.5%	6.9%	7.3%	7.3%	4.3%	5.3%	5.9%	7.4%
Adjusted EPS before taxes	18.7%	(11.1B)	(11.1B)	78.1%	4.9%	98.9%	(8.0B)	(5.0B)	(14.9B)	(17.1B)	78.8%
Accounts Receivable	4.6%	(8.1B)	4.9%	4.0%	(6.0B)	5.9%	(8.0B)	(5.0B)	9.9%	(9.7B)	7.7%
Inventory	17.4%	(1.0B)	16.6%	17.0%	(4.1B)	8.0%	(1.1B)	6.6%	17.4%	11.9%	17.4%
Net PP&E	(1.0B)	(5.7B)	7.0%	7.0%	17.7%	(7.7B)	(6.0B)	8.0%	5.1%	6.3%	6.3%
Total Assets	(7.0B)	7.0%	6.9%	7.0%	(5.7B)	(10.0B)	(17.7B)	(5.0B)	7.4%	7.0%	17.4%
Tangible Book Value	(104.0B)	(110.0B)	587.5%	747.1%	(89.7B)	(143.0B)	(95.7B)	(18.0B)	(17.12x)	477.7%	763.7%
Common Equity	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%	6.7%
Cash from Ops.	(2.9B)	(16.7B)	(15.7B)	(75.1B)	19.7%	27.0%	17.3%	24.7%	6.7%	(11.7B)	16.1%
Capital Expenditures	37.4%	17.7%	27.7%	27.7%	20.7%	20.7%	20.7%	20.7%	20.7%	20.7%	20.7%
Invested Free Cash Flow	(29.0B)	(17.0B)	(29.0B)	(15.7B)	22.3%	66.7%	19.0%	17.3%	6.0%	(14.0B)	18.6%
Undivided Free Cash Flow	(194.7B)	(187.0B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)	(194.7B)
Dividend per Share	4.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%
F&B Over Three Years											
Total Revenue	(7.0B)	(5.0B)	(7.0B)	(5.0B)	(4.0B)	(7.1B)	5.8%	6.0%	6.0%	6.0%	7.4%
Gross Profit	(7.0B)	(5.0B)	(7.0B)	(5.0B)	(4.0B)	(4.0B)	6.0%	6.0%	6.0%	6.0%	7.4%
EBITDA	(7.0B)	7.7%	(5.7B)	(10.0B)	(5.0B)	(5.0B)	7.7%	7.7%	(9.0B)	(7.7B)	7.7%
EBT	(8.0B)	8.7%	(5.0B)	(10.0B)	(10.0B)	(10.0B)	8.7%	8.7%	(9.0B)	(10.0B)	7.7%
EBT	(7.0B)	9.0%	(6.0B)	(7.0B)	(10.0B)	(7.0B)	9.0%	9.0%	(7.7B)	(11.0B)	8.4%
Earnings from Cont. Ops	10.1%	—	—	8.4%	—	—	8.4%	8.4%	(10.0B)	8.4%	—
Net Income	17.0%	47.3%	—	(8.0B)	166.4%	(7.0B)	(15.0B)	4.9%	(7.7B)	(7.7B)	—
Normalized Net Income	(10.0B)	—	—	(6.0B)	11.1%	(7.0B)	(11.0B)	9.0%	(17.7B)	7.0%	—
Adjusted EPS before taxes	10.4%	37.0%	—	(6.0B)	11.1%	(7.0B)	(11.0B)	9.0%	(17.7B)	7.0%	—
Accounts Receivable	4.6%	1.7%	4.6%	6.7%	(10.0B)	(1.0B)	(7.0B)	(1.0B)	9.9%	7.8%	(1.0B)
Inventory	10.7%	1.8%	15.4%	11.0%	5.9%	5.9%	1.0%	7.0%	5.0%	10.1%	(6.0B)
Net PP&E	0.4%	(1.0B)	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%
Total Assets	1.0%	3.0%	6.0%	4.7%	(5.7B)	(4.0B)	(1.0B)	0.0%	0.0%	(7.0B)	(6.0B)
Tangible Book Value	—	—	6.0%	0.0%	—	(47.0B)	(4.0B)	60.1%	—	(5.0B)	(21.0B)
Common Equity	7.0%	10.7%	5.9%	5.9%	0.7%	(5.0B)	(5.0B)	(5.0B)	(5.0B)	(5.0B)	0.0%
Cash from Ops.	(13.0B)	(14.0B)	(10.0B)	(11.0B)	(5.0B)	17.1%	(4.0B)	0.5%	17.8%	16.7%	17.7%
Capital Expenditures	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%
Invested Free Cash Flow	(16.0B)	(76.0B)	(16.0B)	(17.0B)	(7.0B)	70.0%	(8.0B)	(6.0B)	14.9%	10.0%	18.6%
Undivided Free Cash Flow	(11.7B)	(4.0B)	—	(17.0B)	48.9%	48.9%	(7.7B)	6.0%	4.9%	4.9%	4.9%
Dividend per Share	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%
F&B Over Three Years											
Total Revenue	(7.0B)	(7.0B)	0.0%	5.0%	0.4%	(1.0B)	(1.0B)	(1.0B)	(1.0B)	(1.0B)	1.0%
Gross Profit	(10.1B)	0.0%	1.4%	0.0%	1.4%	(10.1B)	(10.0B)	(10.0B)	(10.0B)	(10.0B)	1.0%
EBITDA	(7.0B)	0.4%	11.0%	0.4%	0.4%	0.4%	(7.0B)	(7.0B)	(7.0B)	(7.0B)	0.4%
EBT	(7.0B)	4.1%	(10.0B)	(10.0B)	(10.0B)	(10.0B)	4.1%	4.1%	(10.0B)	(10.0B)	4.0%
EBT	(11.1B)	7.0%	(10.0B)	11.7%	10.1%	10.1%	0.0%	0.0%	(4.1B)	(10.0B)	7.1%
Earnings from Cont. Ops	16.0%	(7.0B)	(14.0B)	7.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%	6.0%
Net Income	36.1%	(4.0B)	(17.7B)	17.4%	48.7%	19.0%	(19.0B)	(19.0B)	(19.0B)	(19.0B)	18.0%
Normalized Net Income	7.4%	(10.0B)	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%	17.7%
Adjusted EPS before taxes	34.9%	(6.7B)	(14.4B)	14.7%	8.9%	17.8%	(16.0B)	(16.0B)	(16.0B)	(17.0B)	18.5%
Accounts Receivable	7.4%	(1.0B)	3.7%	4.6%	0.5%	3.1%	0.0%	7.0%	7.7%	(7.0B)	0.9%
Inventory	8.4%	4.8%	11.0%	11.0%	6.7%	4.0%	4.0%	4.0%	4.0%	4.0%	4.0%
Net PP&E	0.5%	(1.0B)	5.1%	5.1%	1.0%	7.0%	7.0%	7.0%	7.0%	7.0%	7.0%
Total Assets	4.0%	5.0%	8.1%	6.0%	(10.0B)	(1.0B)	0.0%	(10.0B)	(10.0B)	(10.0B)	7.8%
Tangible Book Value	(159.7B)	(162.2B)	2.5%	(10.5B)	(136.3B)	(34.7B)	(45.0B)	(9.3B)	(7.6B)	(12.3B)	(29.5B)
Common Equity	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%	0.1%
Cash from Ops.	0.1%	(2.0B)	(2.0B)	(7.2B)	3.6%	4.7%	0.6%	(1.1B)	1.2%	1.8%	4.4%
Capital Expenditures	3.8%	5.1%	5.0%	5.1%	3.4%	3.8%	4.2%	3.1%	6.7%	5.1%	4.9%
Invested Free Cash Flow	(0.5B)	(0.5B)	(4.1B)	(4.1B)	3.4%	3.8%	(152.2B)	(8.4B)	(1.5B)	(0.8B)	4.0%
Undivided Free Cash Flow	(6.0B)	(20.0B)	(195.4B)	(141.4B)	3.7%	6.7%	(152.2B)	(8.4B)	(1.5B)	(0.8B)	4.0%
Dividend per Share	6.1%	6.1%	6.1%	5.7%	5.7%	5.7%	5.7%	5.5%	5.5%	5.5%	4.2%

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Capital Structure										
For the Fiscal Period Ending Currency	31/03/2024		30/06/2024		29/09/2024		29/12/2024		30/03/2025	
	USD		USD		USD		USD		USD	
	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total	Millions	% of Total
Hot Market Cap										
CT Revenue	8,550.0	2.1%	9,855.0	2.5%	4,460.0	1.1%	5,983.0	1.5%	13,897.0	3.1%
LT Borrowings	25,082.0	6.1%	31,636.0	8.2%	31,289.0	7.4%	31,851.0	8.2%	38,355.0	8.6%
Pref Equity	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital	414,351.5	100.0%	393,275.6	100.0%	424,288.9	100.0%	386,958.0	100.0%	446,076.9	100.0%

[illegible]

Credit Ratios					
Net Debt/EBITDA	0.3x	0.5x	0.5x	0.5x	0.5x
Total Debt/EBITDA	1.1x	1.4x	1.2x	1.3x	1.8x
Operating Income/Total Debt	0.2x	0.2x	0.1x	0.1x	0.1x
LYM FCF/Total Debt	0.6x	0.5x	0.6x	0.5x	0.4x
LYM CFI/Total Debt	0.7x	0.6x	0.7x	0.7x	0.5x
FRIT/Interest Expense	39.2x	23.2x	26.3x	26.5x	30.4x
FRIT/Total Interest Expense	39.2x	23.2x	26.3x	26.5x	30.4x
Degree of Financial Leverage	1.0x	1.0x	1.0x	1.0x	1.0x
EBITDA-CAPEX/Interest Expense	45.7x	26.2x	30.5x	28.5x	35.2x
EBITDA/Total Interest Expense	50.9x	29.8x	30.3x	30.3x	39.1x

Debt Schedule										
Debt Schedule In Yr 1	--	--	--	--	--	1,749.0	5.4%	--	--	
Debt Schedule In Yr 2	--	--	--	--	--	1,999.0	6.2%	--	--	
Debt Schedule In Yr 3	--	--	--	--	--	2,385.0	7.4%	--	--	
Debt Schedule In Yr 4	--	--	--	--	--	2,275.0	7.0%	--	--	
Debt Schedule In Yr 5	--	--	--	--	--	1,444.0	4.5%	--	--	
Debt Schedule - Years 2 - 3	--	--	--	--	--	4,384.0	13.3%	--	--	
Debt Schedule - Years 4 - 5	--	--	--	--	--	3,719.0	11.5%	--	--	
Debt Schedule - Years 2 - 5	--	--	--	--	--	8,103.0	25.0%	--	--	
Debt Schedule Beyond Yr 5	--	--	--	--	--	22,548.0	69.0%	--	--	
Debt Schedule - Total Debt	25,082.0	100.0%	31,636.0	100.0%	31,289.0	100.0%	32,400.0	100.0%	52,252.0	100.0%

Capital Lease Schedule	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	
------------------------	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	--

[illegible]

Contractual Obligation Schedule										
Contractual Obligations - Year 1	--	--	--	--	--	--	5,360.0	11.0%	--	--
Contractual Obligations- Years 2-3	--	--	--	--	--	--	6,435.0	13.2%	--	--
Contractual Obligations- Years 4-5	--	--	--	--	--	--	5,618.0	11.5%	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--	--	12,053.0	24.7%	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--	--	31,469.0	64.4%	--	--
Total Contractual Obligations	--	--	--	--	--	--	48,882.0	100.0%	--	--

Purchase Obligations	--	--	--	0.0	--
----------------------	----	----	----	-----	----

Interest Rate Data				
W/Avg. Interest Rate - Long-term Debt	2017	2018	2019	2020
	3.50%	3.50%	3.50%	3.50%

JNJ US EQUITY	Ascend	▼
Consolidated	Yes	▼

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

[illegible]**OPERATING PROFIT BEF TAX****OPERATING PROFIT BEF TAX**

Ticker: JNJ US EQUITY

SortAscend

CurrencyReportingChangeUSD

Period TypeAnnuals

ConsolidatedYes

AccountingMixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022	01/01/2023	31/12/2023	29/12/2024
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	882.00	1,037.00	949.00	1,080.00	1,283.00	1,163.00	1,380.00	1,421.00	1,319.00	893.00	948.00
Interest Cost	1,018.00	988.00	927.00	927.00	996.00	1,096.00	955.00	770.00	908.00	1,437.00	1,402.00
Expected Return on Plan Assets	(1,607.00)	(1,809.00)	(1,962.00)	(2,041.00)	(2,212.00)	(2,322.00)	(2,461.00)	(2,645.00)	(2,756.00)	(2,716.00)	(2,560.00)
Pension Expense (Income)	743.00	971.00	422.00	594.00	923.00	593.00	790.00	623.00	(62.00)	(676.00)	(222.00)
Other Postretirement Cost											
Service Cost	211.00	257.00	224.00	247.00	269.00	274.00	287.00	309.00	320.00	264.00	277.00
Interest Cost	197.00	186.00	158.00	159.00	148.00	185.00	133.00	81.00	104.00	214.00	209.00
Expected Return on Plan Assets	(7.00)	(7.00)	(6.00)	(6.00)	(7.00)	(6.00)	(7.00)	(7.00)	(8.00)	(7.00)	(7.00)
Other Postretirement Benefits Expense (I	503.00	604.00	477.00	508.00	502.00	551.00	524.00	503.00	533.00	487.00	530.00
Pension Funded Status											
Fair Value of Plan Assets	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00	31,496.00	33,607.00	33,395.00
Actual Return (Loss) on Plan Assets	2,078.00	298.00	2,286.00	4,274.00	(1,269.00)	6,185.00	5,524.00	4,439.00	(8,663.00)	3,951.00	2,113.00
Employer Contribution	1,176.00	752.00	838.00	664.00	1,140.00	908.00	870.00	969.00	261.00	268.00	229.00
Benefits Paid	(813.00)	(773.00)	(1,210.00)	(1,050.00)	(1,018.00)	(1,555.00)	(1,111.00)	(1,157.00)	(1,220.00)	(2,122.00)	(1,801.00)
Projected Benefit Obligation	26,889.00	25,855.00	28,116.00	33,221.00	31,670.00	37,188.00	43,300.00	41,582.00	29,390.00	31,744.00	30,317.00
Over(Under) Funded Pension	(4,314.00)	(3,601.00)	(4,483.00)	(4,817.00)	(4,852.00)	(4,987.00)	(5,105.00)	348.00	2,106.00	1,863.00	3,078.00
Accumulated Benefit Obligation	23,816.00	23,262.00	25,319.00	29,793.00	28,533.00	33,416.00	40,356.00	39,049.00	27,797.00	30,139.00	28,883.00
Pension Funding Ratio	83.96	86.07	84.06	85.50	84.68	86.59	88.21	100.84	107.17	105.87	110.15
Other Postretirement Funded Status											
Fair Value of Plan Assets	79.00	74.00	75.00	281.00	180.00	115.00	90.00	102.00	78.00	86.00	93.00
Actual Return (Loss) on Plan Assets	8.00	1.00	7.00	12.00	-	19.00	14.00	17.00	(17.00)	16.00	15.00
Employer Contribution	477.00	414.00	372.00	545.00	282.00	347.00	357.00	343.00	386.00	694.00	548.00
Benefits Paid	(493.00)	(420.00)	(378.00)	(351.00)	(383.00)	(431.00)	(396.00)	(348.00)	(393.00)	(702.00)	(556.00)
Projected Benefit Obligation	5,081.00	4,669.00	4,605.00	4,582.00	4,480.00	5,076.00	5,028.00	4,878.00	4,192.00	4,108.00	4,425.00
Over(Under) Funded Post Ret Benefits	(5,002.00)	(4,595.00)	(4,530.00)	(4,301.00)	(4,300.00)	(4,961.00)	(4,938.00)	(4,776.00)	(4,114.00)	(4,022.00)	(4,332.00)
Other Post-Retirement Funding Ratio	1.55	1.58	1.63	6.13	4.02	2.27	1.79	2.09	1.86	2.09	2.10
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	8.46	8.53	8.55	8.43	8.46	8.31	8.12	7.71	7.25	7.21	7.25
Discount Rate used on Plan Liabilities	3.78	4.11	3.78	3.30	3.76	2.91	2.14	2.49	5.01	4.58	4.39
Rate of Compensation Increase	4.08	4.05	4.02	4.01	3.98	3.99	4.00	4.01	4.00	3.69	3.70
Other Postretirement Benefits											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	5.25	4.31	4.77	4.63	3.85	3.39	2.23	2.68	5.01	4.58	4.95
Health Care Cost Trend Projected(next y	6.00	6.60	6.32	6.33	6.12	5.87	5.68	5.33	5.96	13.90	9.33
Pension Plan Asset Allocation											
Fair Value of Plan Assets	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00	31,496.00	33,607.00	33,395.00
Asset Category - Equities %	77.00	79.00	75.00	76.00	71.00	74.00	66.00	65.00	62.00	58.00	55.00
Asset Category - Debt %	23.00	21.00	25.00	24.00	29.00	26.00	34.00	35.00	38.00	42.00	45.00
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Other %	-	-	-	-	-	-	-	-	-	-	-
Expected Pension Payments											
Year 1	793.00	839.00	897.00	970.00	1,062.00	1,126.00	1,257.00	1,317.00	1,445.00	1,481.00	1,480.00
Year 2	813.00	872.00	908.00	1,007.00	1,104.00	1,172.00	1,292.00	1,386.00	1,457.00	1,473.00	1,503.00
Year 3	868.00	911.00	958.00	1,057.00	1,182.00	1,234.00	1,388.00	1,421.00	1,532.00	1,549.00	1,604.00
Year 4	907.00	967.00	1,010.00	1,131.00	1,257.00	1,323.00	1,424.00	1,496.00	1,609.00	1,647.00	1,702.00
Year 5	963.00	1,031.00	1,081.00	1,190.00	1,332.00	1,359.00	1,494.00	1,572.00	1,708.00	1,745.00	1,797.00
Beyond Year 5	5,858.00	6,098.00	6,416.00	7,062.00	7,679.00	7,945.00	8,795.00	9,279.00	10,034.00	10,133.00	10,401.00
Expected Postretirement Benefits											
Year 1	316.00	331.00	325.00	322.00	375.00	437.00	427.00	447.00	471.00	427.00	464.00
Year 2	309.00	322.00	315.00	312.00	397.00	450.00	440.00	459.00	485.00	438.00	478.00
Year 3	306.00	315.00	311.00	306.00	411.00	466.00	453.00	472.00	433.00	396.00	432.00
Year 4	303.00	312.00	307.00	301.00	428.00	479.00	465.00	485.00	447.00	411.00	445.00
Year 5	300.00	310.00	304.00	297.00	413.00	494.00	417.00	434.00	462.00	428.00	462.00
Beyond Year 5	1,475.00	1,499.00	1,465.00	1,395.00	2,273.00	2,356.00	2,273.00	2,379.00	2,539.00	2,360.00	2,537.00

Johnson & Johnson
Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

[illegible]